The fierce battle between weight-loss drug makers has led to sky-high Wall Street expectations, with investors anticipating new medicines that are incrementally more powerful and easier to take. Now, the industry may be hitting a ceiling, and some experts say investors’ obsession with continually increasing weight loss may be misguided. Mizuho’s Jared Holz speaks with Scarlet Fu on “Bloomberg Markets”. (Source: Bloomberg)
Visited 1 times, 1 visit(s) today
